" "
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Affymetrix Announces Research Collaboration with MGH

Published: Thursday, June 07, 2012
Last Updated: Thursday, June 07, 2012
Bookmark and Share
Collaboration and licensing agreement to validate and develop new oncology biomarker tests.

Affymetrix, Inc. has announced a research collaboration and licensing agreement with Massachusetts General Hospital (MGH) to co-develop new cancer biomarker tests using the Affymetrix’ QuantiGene® ViewRNA Assay platform, an in situ hybridization assay capable of single transcript in single-cell detection.

As part of this agreement, Affymetrix has the rights to commercialize the new biomarker tests as an outcome of this collaboration.

“This agreement provides Affymetrix with an important opportunity to expand its QuantiGene ViewRNA Assay offering into the pathology and cancer research markets by providing new multiplex chromogenic in situ hybridization (CISH) and fluorescence in situ hybridization (FISH) RNA biomarker assays which are validated on clinical samples for research applications. Advanced in situ RNA hybridization methods applied to less invasive clinical samples such as FFPE core biopsies, FNAs, and CTCs has the potential of becoming powerful new tools to deliver diagnostics that enable the oncologist to personalize patient care,” stated George Bers, Vice President and General Manager, Gene Expression Business Unit Manager - Panomics at Affymetrix.

Currently, those who practice surgical pathology and cytology face challenges in the management of a broad range of cancers.

Medical practitioners are optimistic that a solution to these challenges will be found in new biomarkers and drug targets which are being rapidly discovered by NGS and microarray technologies.

Yet these new biomarker discoveries have in themselves become a challenge requiring extensive validation prior to becoming candidates for translation into diagnostic, prognostic, and predictive tests to fulfill the promise of delivering a new generation of personalized medicine and associated economic and healthcare outcomes.

"The future of cancer treatment lies in our ability to precisely identify specific biomarkers so we can then find effective drugs for that particular form of disease,” said Daniel A. Haber, MD, PhD, director of the MGH Cancer Center. “This collaboration with Affymetrix aims to move this important work forward."

MGH is a world leader in cancer research and education, translational medicine, and a major center for patient care. MGH has some of the world’s largest annotated tissue banks for retrospective biomarker studies as well as large and diverse patient populations for prospective studies.

MGH’s Cancer Center and Department of Pathology are currently collaborating with Affymetrix to validate biomarkers of current and future clinical importance using Affymetrix’ QuantiGene ViewRNA technology platform for multiplex in situ testing of FFPE tissue biopsies, FNA cytologies, and CTC “liquid biopsies”.

QuantiGene ViewRNA is an ideal platform for cancer biomarker validation and testing as RNA is a predictable, sensitive and specific alternative to antibody based IHC and ICC testing.

QuantiGene ViewRNA probes for RNA assays can be developed for research applications for any expressed gene within days and can analyze non-coding RNAs believed to be important master regulators of cancer and for which antibody assays can’t be developed.

To date, the research collaboration has produced several potential diagnostic/prognostic biomarker targets including new class of non-coding RNA, HSATII, and EGFR vIII.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bio-Genesys, Affymetrix Partner
Partnership to offer animal genomic testing services to professional farming operations.
Wednesday, January 13, 2016
Thermo Fisher Scientific to Acquire Affymetrix
Strengthens leadership in biosciences and genetic analysis.
Monday, January 11, 2016
Affymetrix, Reveal Biosciences Partner
Partnership agreement to offer RNA ISH tissue staining, imaging, and image analysis services.
Thursday, December 03, 2015
Affymetrix and Athletigen Partner
Partnership agreement to advance genetics in human athletic performance.
Thursday, October 29, 2015
Affymetrix and Luminex Announce Distribution Agreement
Agreement for multiplexed assay instrument platform.
Friday, October 16, 2015
Green Super Rice Project Selects Affymetrix Genotyping Platform for Developing New Rice Varieties
The Green Super Rice (GSR) project includes building a highly efficient genotyping platform for the large-scale molecular breeding activities within the international rice research community.
Tuesday, September 22, 2015
Affymetrix, BioRealm, RUCDR Ally
Affymetrix, BioRealm, and RUCDR Infinite Biologics today announced a strategic alliance to genotype the National Institute of Drug Abuse biorepository.
Wednesday, July 08, 2015
Affymetrix Acquires Assets of Eureka Genomics
Aquisition will enable provision of high throughput and economical crop and animal genotyping.
Thursday, May 14, 2015
CollabRx, Affymetrix To Develop Analytical Tools For Integrated Clinical Cancer Panels
The overall objective of the partnership is to provide scientific knowledge for biomarker CNV profiles in cancer.
Wednesday, April 16, 2014
University of Bristol Collaborates with Affymetrix on Genotyping Arrays
Results from the array presented at the 2014 Plant and Animal Genome conference.
Wednesday, January 15, 2014
Affymetrix Reports 2013 First Quarter Results
Affymetrix, Inc. reported its operating results for the three months ended March 31, 2013.
Wednesday, May 01, 2013
Affymetrix and BioDiscovery Announce Software for Analysis of Whole Genome Copy Number Data
Generated from FFPE solid tumor samples for accelerating cancer translational research.
Thursday, April 11, 2013
Ingenuity Systems and Affymetrix Partner
Companies collaborate to eliminate microarray expression analysis bottleneck.
Monday, April 08, 2013
Affymetrix Announces Collaboration with Centre for Proteomic and Genomic Research (CPGR)
CPGR will provide gene expression and Axiom genotyping services to African researchers using GeneTitan® Multi-Channel (MC) Instrument.
Tuesday, November 20, 2012
Affymetrix and Singapore-based Start-up PathGEN Dx Sign Partnership
Agreement for diagnostic test development for pathogen detection.
Monday, August 27, 2012
Scientific News
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!